The article discusses the impact of adding cetuximab to conventional definitive chemoradiotherapy (dCRT) in the treatment of localized esophageal cancer. Topics include the worse survival and greater toxicity demonstrated by the addition of cetuximab, the unprecedented survival in the dCRT arm compared to surgical trials, and the good results with chemoradiation that patients who are not at risk of curative surgery of localized esophageal cancer might experience.